Niclosamide Nanoparticles (eNDN): A 10× Bioavailability Breakthrough Against PEDV

Porcine Epidemic Diarrhea Virus keeps swine producers up at night — and for good reason. This α-coronavirus tears through the intestinal lining of pigs with brutal efficiency. Newborn piglets are the hardest hit. Once infected, mortality runs high, and the few that survive rarely catch up on growth. The virus first surfaced in Europe decades ago. Since then, it has spread to China, the United States, South Korea, and Japan. It mutates relentlessly. New strains appear with higher virulence and sharper transmissibility, outpacing vaccine development. The industry bleeds billions every year. And after all this time, there is still no approved antiviral drug that specifically targets PEDV.

Some researchers looking at this problem took an unexpected turn. Instead of designing a new molecule from scratch, they dug through the existing pharmacopeia. Their attention landed on niclosamide — a drug that has been sitting on pharmacy shelves since the 1950s, prescribed almost exclusively for tapeworm infections.

A Dewormer That Kills Viruses

For most of its history, niclosamide was a one-trick molecule: it killed intestinal parasites. Then, sometime in the last decade, it started showing up in antiviral screens. Against SARS-CoV. Against MERS-CoV. Against Zika virus. Against hepatitis C. Each time, the same pattern — the drug was active, and at surprisingly low concentrations.

When COVID-19 hit, niclosamide got a second look. Researchers working on SARS-CoV-2 found that it blocked TMEM16F, a host-cell protein the virus uses to fuse infected cells into giant syncytia. It gummed up the viral proteases PLpro and 3CLpro. It suppressed NLRP3, AIM2, and NAIP/NLRC4 inflammasomes — the same inflammatory machinery that drives the cytokine storms seen in severe coronavirus infections. Rather than going after the virus directly, niclosamide went after the host machinery the virus depends on. That is an unusual strategy for an antiviral, and it helps explain why the drug works across such a wide range of viruses.

PEDV and SARS-CoV-2 are cousins. Both belong to the Coronaviridae family. If niclosamide blocked one coronavirus through host-targeted mechanisms, there was a reasonable chance it would block another. The researchers tested that hypothesis in cell culture, and the numbers came back strong.

What the Lab Data Shows

Vero cells infected with the PEDV DR13 strain responded sharply to niclosamide. The IC50 — the concentration that cuts viral activity by half — was 226.4 nmol/L. That puts it ahead of remdesivir, hydroxychloroquine, and ivermectin on potency against comparable coronaviruses. The selectivity index, which compares antiviral activity to cellular toxicity, hit 257.1. For reference, anything above 10 is promising and anything above 100 is exceptional. The drug was killing the virus at concentrations far below what would harm the host cells.

Plaque assays backed this up. At 50 nmol/L, the drug visibly reduced viral plaques. At 500 nmol/L, plaques disappeared entirely. Not slowed down — gone.

None of this mattered for a real-world application, though, because niclosamide has a fatal flaw as a systemic drug: it barely dissolves.

The Solubility Wall

Niclosamide’s aqueous solubility is roughly 5 to 8 micrograms per milliliter at room temperature. That is close to zero in pharmacokinetic terms. Swallow a pill of raw niclosamide, and almost none of it enters your bloodstream. The drug stays in the gut, does its antiparasitic work locally, and gets excreted. For tapeworms living in the intestinal lumen, that is perfectly fine. For a systemic viral infection, it is useless.

Poor solubility is not a niche problem. It kills something like 70% of drug candidates in development. The molecule has activity on paper, but no viable route into the body. Niclosamide was stuck in exactly that graveyard — potent in a petri dish, worthless in a patient.

The researchers already had one attempt at solving this. Their first-generation nanoparticle formulation, called NDN, used a bile acid coating — specifically cholate — to wrap niclosamide molecules into nanoscale particles. Bile acids are not just digestive helpers. The small intestine has a dedicated transporter, the apical sodium-dependent bile acid transporter (ASBT), that actively pulls bile acids from the gut lumen into intestinal cells. By dressing niclosamide in cholate, the drug hitches a ride on this transporter. Absorption jumps.

NDN was a real step forward. Water solubility reached 4 mg/mL — roughly 800 times better than raw niclosamide. Oral bioavailability reached 38.3%. Peak blood concentration arrived in about 15 minutes, confirming the ASBT shuttle was functioning. But NDN had gaps. Gastric acid stability was poor. The particle size and bioavailability had room to shrink and grow, respectively.

The Upgrade: Enter eNDN

The researchers added one ingredient to the formulation: Poloxamer F-127. This is an FDA-approved block copolymer that shows up in all kinds of pharmaceutical preparations. It forms protective micelles around drug molecules, stabilizes them against acidic environments, and improves both solubility and absorption. It is the kind of excipient that formulation scientists reach for when they need something to work a little better.

The enhanced nanoparticles, eNDN, came out at about 140 nm in diameter — around 30 nm smaller than NDN — with a polydispersity index of 0.19, meaning the particles were uniform. Scanning electron microscopy showed flower-like spheres. Water solubility rose to 5 mg/mL, a 20% improvement. But the real story was in the pharmacokinetics.

Rats given oral eNDN showed a fundamentally different drug profile than those given raw niclosamide. Half-life stretched from 2.55 hours to 6.52 hours. Time to peak concentration dropped from 1.6 hours to 0.35 hours. Peak blood concentration jumped by a factor of 11.49, from around 92 ng/mL to over 1,061 ng/mL. Absolute oral bioavailability hit 47.54%, compared to 4.75% for unformulated niclosamide. That is a tenfold increase, and it puts eNDN in the range considered viable for oral drug development. For a compound that was essentially unabsorbable, the transformation is hard to overstate.

Safety looked clean. Mice received eNDN at up to 80 mg/kg twice daily for a week, or a single massive dose of 160 mg/kg. No deaths. No changes in body weight, body temperature, coat condition, or stool. Liver histopathology at the highest doses showed nothing abnormal. The cholate carrier and Poloxamer F-127 — both biocompatible, both well-characterized — appear to have done their job without collateral damage.

The Animal Data That Actually Counts

Cell culture data is cheap. The real test was in APN transgenic mice — animals engineered to express porcine aminopeptidase N, which makes them susceptible to PEDV infection. Mice were orally challenged with the virus, then treated with either saline, unformulated niclosamide, or eNDN. After seven days, intestinal tissue was analyzed by quantitative PCR.

The results were unambiguous. The eNDN group showed viral titers that were a fraction of the control group — statistically, the difference was clear at P<0.01. Unformulated niclosamide nudged the viral load downward, but the effect did not reach significance. The nanoparticle formulation was not a marginal improvement. It was the difference between a drug that shows activity in a test tube and a drug that works in a living animal.

What Niclosamide Is Actually Doing Inside the Cell

The mechanism here is not a single target. It is a network, and the researchers used a combination of literature mining, bioinformatics, and molecular docking to map it.

They identified 159 known niclosamide targets and 1,678 PEDV-related host targets. Only 22 overlapped. Protein-protein interaction analysis narrowed those to eight core nodes: TP53, STAT3, MAPK14, MCL1, SERPINE1, RHOA, MAPK1, and DDIT3. Gene ontology enrichment pointed toward apoptosis regulation, lipopolysaccharide response, interleukin-8 production, and damage response pathways. KEGG analysis flagged lipid metabolism, AGE-RAGE signaling, and C-type lectin receptor pathways.

Molecular docking then tested binding affinity computationally. Of the 22 candidate targets, 14 showed favorable scores. The top ten, ranked by binding strength, were MAPK14, NAIP, NLRC4, SERPINE1, ATP2A2, CLTC, MCL1, TMPRSS2, APN, and STAT3.

A few of these targets are worth examining individually, because they tell a coherent story about how the drug works.

MAPK14 (p38α MAPK) is a kinase at the center of pro-inflammatory signaling. SARS-CoV-2 activates this pathway to boost its own replication. Niclosamide inhibits it. NAIP and NLRC4 form an inflammasome complex. During viral infection, this complex can drive excessive inflammation; modulating it helps keep the immune response from becoming self-destructive. SERPINE1 (plasminogen activator inhibitor-1) sits at the crossroads of coagulation and inflammation. Coronaviruses push SERPINE1 expression up, contributing to the clotting problems that make these infections dangerous. In PEDV specifically, SERPINE1 promotes the release of new viral particles from infected cells. CLTC (clathrin heavy chain) mediates the endocytosis that viruses exploit to enter cells — block CLTC, and you block viral entry. TMPRSS2 is a protease that cleaves viral spike proteins, a prerequisite for membrane fusion. APN is a transmembrane enzyme that PEDV uses as a binding receptor. STAT3 is a transcription factor governing cell growth, inflammation, and immune evasion.

Taken together, the mechanism looks like this: niclosamide simultaneously dampens the inflammatory overreaction, blocks multiple viral entry routes, and disrupts host processes the virus needs to replicate. It does not lock onto one protein and hope for the best. It cuts several supply lines at once.

This also helps explain why resistance does not seem to be a major concern with niclosamide the way it is with single-target antivirals. Evolving around one blocked pathway is evolutionarily manageable for a virus. Evolving around four or five blocked pathways simultaneously is a much harder problem.

From the Bench to the Barn

PEDV will not disappear on its own. The virus keeps generating variants. The economic damage is concentrated in newborn piglets, which have the least developed immune systems and the highest mortality. There is no vaccine that works reliably across all strains, and no approved antiviral.

eNDN checks several boxes that matter for practical deployment. It is oral — injecting thousands of piglets individually is a logistical nightmare, but adding a drug to feed or water is straightforward. It uses a drug that is already approved, widely available, and cheap to manufacture. Its host-directed mechanism is less vulnerable to viral mutation than direct-acting antivirals that target a single viral protein. And it has safety and efficacy data from animal studies, not just cell culture.

The gaps are real, and they deserve honesty. The APN transgenic mouse model, while useful, does not reproduce the full pathology of PEDV — infected mice do not develop the watery diarrhea and intestinal lesions characteristic of the disease in piglets. Testing in actual piglet models, or in transgenic models with better clinical fidelity, is the next logical step. Gastric acid stability in eNDN improved compared to NDN, but it still falls well short of the 95% benchmark typical for oral formulations. Regulatory frameworks for veterinary nanomedicines are not settled in most countries. The path from here to a commercial product is years long and expensive.

But the fundamentals are solid. A cheap oral antiviral against a pathogen that costs the swine industry billions each year, built on a delivery platform that has already shown efficacy against SARS-CoV-2 in hamster and transgenic mouse models — that is not vaporware. It is a lead worth following.

The broader lesson is as interesting as the specific drug. Many compounds fail in development not because they lack activity, but because they cannot reach their target. The ASBT-cholate-Poloxamer platform is a reminder that delivery can be engineered separately from the drug itself. Find a bioactive molecule. Wrap it in the right nanoparticle. Suddenly, a drug that was useless systemically becomes useful. This pattern applies beyond niclosamide and beyond PEDV. It applies to any poorly soluble compound with good pharmacology and bad pharmacokinetics — in veterinary medicine, in human medicine, for pathogens we know about and for ones we have not met yet.